Chinese Language – Talk Bio

Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

1 week ago talkbio0Tagged Chinese Language, Clinical Research, Gan & Lee Pharmaceuticals, Glucagon-Like Peptide 1, GRADUAL-3, innovation, once-monthly, Phase 3, Rheumatoid Arthritis, Weight maintenance regimen

Gan & Lee Pharmaceuticals; Phase 3 clinical study; GRADUAL-3; once-monthly GLP-1 RA; weight management; Chinese innovation

Chinese Biotechs Shed Fast-Follower Reputations as Innovation Surges in 2025

3 weeks ago talkbio0Tagged Biopharma, China, Chinese Language, Clinical Trials, drug candidates, global drug pipeline, innovation, leader, R&D, regulatory reforms

Chinese biotech innovation; fast-follower to leader; biopharma R&D; global drug pipeline; regulatory reforms; clinical trials; Made in China 2025; novel drug candidates

Ascletis Advances in Obesity Treatment with Promising Oral GLP-1 Data

10 months ago talkbio0Tagged ASC30, Ascletis, Chinese Language, Glucagon-Like Peptide 1, Obesity, Oral cavity, Pharma, pharmaceutical innovation

Ascletis Pharma, oral GLP-1, obesity treatment, weight loss, ASC30, Chinese biotech, pharmaceutical innovation

FDA Issues Import Alerts for Two Chinese API Manufacturers Following Failed Inspections

10 months ago talkbio0Tagged alpha 1-antitrypsin, Chengdu, Chinese Language, Dosage Forms, Failed, import alert, innovation, Inspection (procedure), manufacturers, Quality, Science of Chemistry, United States Food and Drug Administration, Wuhu

FDA, import alert, Chinese API manufacturers, failed inspections, quality control, Wuhu Nuowei Chemistry, Chengdu Innovation Pharmaceutical

BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs

12 months ago talkbio0Tagged BIOSECURE, Biotechnology, biotechs, Chinese Language, National Security, U.S.

BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

1 year ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

BIOSECURE Act: Navigating Industry Implications and Future Directions

1 year ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience

BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties

1 year ago talkbio0Tagged BIOSECURE, Biotech Companies, Biotechnology, Chinese Language, Drug Industry, drug supply chain, innovation, National Security, Risk, Senate, United States, US House of Representatives, Voting

BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain

US Speaker Promises Vote on BIOSECURE Act to Halt Federal Contracts with Chinese Biotech Companies

1 year ago talkbio0Tagged BIOSECURE, Chinese Language, Contract agreement, federal, Health care facility, House Speaker Mike Johnson, National Security

BIOSECURE Act, House Speaker Mike Johnson, Chinese biotech companies, federal contracts, healthcare data, national security

Western In-Licensing Deals with Chinese Companies: Focus on Disease Areas and Drug Types

1 year ago talkbio0Tagged Biopharma, Chinese Language, cross-border partnerships, in-licensing, Licensing trends, pharmaceutical companies, Type of drug, West (direction)

, In-licensing deals, Chinese pharmaceutical companies, Western pharmaceutical companies, Disease areas, Drug types, Cross-border partnerships, Biopharma, Licensing trends,